We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward.
Vaccine Strategies in Clinical Trials (2016)
Number of Broadly Neutralizing Antibodies Discovered
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward.
Vaccines Clinical Trial Participants by Region
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward.
New HIV Infections by Region (2014)
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward.
Epidemics Successfully Combated with Vaccines (From 1980)
We know that an Vaccines will be an important part of a long-term strategy to end the HIV/AIDS epidemic. The road ahead is long, but a vaccines is possible. Clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward.
Global Investment in Vaccines R&D (2014)
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward.
Patchwork of Prevention for Women: Oral PrEP and the Dapivirine Ring
Participants in the ring efficacy studies will get extended access to the ring via open-label studies. But will they have access to PrEP? This map shows which sites will provide PrEP and which will not. Excerpted from Px Wire.
Dapivirine Ring Results—A snapshot
This infographic provides detailed study design and result information from The Ring Study (IPM 027) and ASPIRE (MTN-020). The lower portion of the infographic charts additional, related studies and the regulatory process before the ring’s earliest possible introduction. Excerpted from Px Wire.
Evidence for HIV Prevention Options
What’s the big picture of ARV-based prevention trial results? This graphic shows the levels of efficacy from each major trial (that’s the square icon) with the confidence intervals around the finding (the bars at either side). Not sure what a confidence interval is? See our one-page Advocates’ Guide to Statistical Terms. For PDF and JPEG versions, please click here.
ASPIRE and The Ring Study Results — A Snapshot
Results from two Phase III multi-country trials (ASPIRE and Ring) studying the 4-week slow-release dapivirine vaginal ring were released at the 2016 Conference on Retroviruses and Opportunistic Infection. This chart details study design and enrollment, gives overall results and breaks results down by age.